Contributed views and analysis · pharmaphorum
Approval is not access: Pilots’ real test is implementation
Writing in pharmaphorum, Varun Sharma argues that a positive medicines decision only matters when the full implementation chain can identify, offer, deliver and monitor access.
Varun SharmaAuthor · 18 August 2026
This is contributed views and analysis written by Varun Sharma. It is not independent reporting about NEUVIOR, and it does not establish PHARMORIS adoption, deployment, commercial traction or publisher endorsement.
A decision is not a delivery pathway
Regulatory authorisation, recommendation, funded local availability, clinical offering, patient uptake and outcome monitoring are different states. Treating them as one headline hides where access is actually blocked.
Measure the implementation chain
The article proposes four practical tests: time from national recommendation to an operational pathway, adjusted regional variation, diagnostic and pathway readiness, and transparent governance of co-investment.
Keep influence and authority separate
Industry can support infrastructure, evidence generation or implementation, but the terms should remain visible and prescribing, procurement and patient-data decisions must stay with authorised institutions.
Questions this record can answer
The facts, without the halo effect.
What is the central argument?
Approval and recommendation are necessary milestones, but patient access depends on funded pathway readiness, diagnostics, clinical offering, uptake, monitoring and accountable local implementation.
What should an implementation pilot measure?
The article proposes measuring time to an operational pathway, adjusted regional variation, diagnostic and pathway readiness, and transparent governance of any industry co-investment.
Is the article evidence that PHARMORIS is in use?
No. The article does not establish a PHARMORIS deployment, customer, clinical outcome, readiness rating or commercial result.